Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last several shares of mine. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good To Be True?”, set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview which I came away with a bad opinion of the company.

Irony of irony, my poor impression of the business has grown steadily, however, the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how and linked intellectual property coming from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) and the first brand new drug program approval ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and numerous therapies, it’s this single remedy and a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the really start of my interest in this particular company. Judging by the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *